Application of Multi-Inflammatory Index to Predict Atrial Fibrillation Risk in Patients with Coronary Heart Disease: A Retrospective Machine Learning Study

应用多重炎症指数预测冠心病患者房颤风险:一项回顾性机器学习研究

阅读:2

Abstract

BACKGROUND: Coronary heart disease (CHD) is a leading cause of mortality worldwide, with atrial fibrillation (AF) being a common complication. Chronic inflammatory responses play a significant role in the relationship between coronary artery disease and AF. This study aims to investigate the value of the multi-inflammatory index (MII) in predicting the occurrence of atrial fibrillation in patients with coronary heart disease. METHODS: A retrospective analysis was conducted on patients who visited our hospital from January 1, 2020, to December 31, 2023, including a total of 1392 patients. Clinical data and laboratory results were collected. Feature selection was performed using the Boruta algorithm. Five machine learning models were constructed: Logistic Regression, Decision Tree, Elastic Net, Light Gradient Boosting Machine (LightGBM), and Multilayer Perceptron. Model performance was evaluated using five-fold cross-validation. SHAP values were utilized to analyze feature importance and model interpretability. RESULTS: The study included 1302 patients without AF and 90 patients with AF. Patients with AF had significantly higher MII compared to those without AF (10.02 vs 4.79). Thirteen variables most related to AF occurrence were selected using the Boruta algorithm. The LightGBM model outperformed others, showing the highest accuracy and calibration in both training and test sets. In the training set, LightGBM achieved an AUC of 0.958, accuracy of 0.851, and sensitivity of 0.943, while in the testing set, it achieved an AUC of 0.757 and accuracy of 0.821. SHAP analysis indicated that age, heart rate, and MII were the primary predictors of AF occurrence. CONCLUSION: The LightGBM model demonstrated adequate sensitivity and accuracy. The multi-inflammatory index plays a crucial role in predicting atrial fibrillation in patients with coronary heart disease.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。